About Feldan
Feldan is a company based in Quebec City (Canada) founded in 2007. Feldan has raised $52.9 million across 9 funding rounds from investors including Amgen, Cystic Fibrosis Foundation and GC Green Cross Lab Cell. Feldan offers products and services including Feldan Shuttle. Feldan operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Quebec City, Canada
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website feldan.com
- Social LinkedIn X
- Total Equity Funding$52.9M (USD)
in 9 rounds
- InvestorsAmgen
& 12 more
Products & Services of Feldan
Feldan offers a comprehensive portfolio of products and services, including Feldan Shuttle.
Peptide-based system for enabling intracellular access to therapeutic targets.
Funding Insights of Feldan
Feldan has successfully raised a total of $52.9M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52.9M
- Total Rounds 9
- First Round $450,000
(Apr 2009)
- Investors Count 13
All 9 funding rounds of Feldan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | – | Series B | – | – | |
| Feb 2025 | – | Series B | – | – | |
| Sep 2024 | $21M | Series B | – | Genesys Capital, Fonds de solidarite FTQ | – |
| Jun 2023 | $16.5M | Series B | – | Invest Quebec, Amgen | |
| Jan 2022 | – | Grant | – | – | |
| Sep 2018 | $12.5M | Series A | – | – | |
| Oct 2015 | $1.7M | Series B | – | – | |
| Mar 2015 | $1.2M | Series A | – | – | |
| Apr 2009 | $450,000 | Grant | – | – | – |
13 investors in total: 13 institutional.
Investors in Feldan
Feldan has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Cystic Fibrosis Foundation and GC Green Cross Lab Cell.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Zynext Ventures is focused on funding disruptive healthcare innovations. | – | zynextventures.com | Pennington, United States | |
Linearis is engaged in metabolomics health testing and AI innovation. | – | linearis.com | Québec, Canada | |
Early-stage life sciences companies are supported through venture capital investments. | – | genesyscapital.com | Toronto, Canada | |
Angel investment network supporting innovative entrepreneurs in Canada. | 2008 | angesquebec.com | Montréal, Canada | |
- | – | fiersucces.com | - | |
Early-stage tech and life sciences focused VC & PE firm | – | stonebridge.co.kr | Seoul, South Korea | |
Offers savings plans, investments, and financing for businesses and individuals. | 1983 | fondsftq.com | Montreal, Canada | |
Business guidance for corporate companies and startups | – | investquebec.com | Quebec City, Canada | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Cell and gene therapy products are researched, developed, and manufactured. | 2008 | gccell.com | - |
Investor details for Feldan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Feldan
3 dated milestones of Feldan across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Feldan is founded.
- Funding First funding round of $450K.
- Funding Latest funding round, Series B,.
Competitors of Feldan
Feldan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Feldan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Feldan
The website of Feldan (feldan.com) receives about 1K visits a month.
- Monthly visits1K
▲ 227.8% vs previous month
Websites whose visitors overlap most with Feldan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Latest news on Feldan
Complete news archive for Feldan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Feldan
10 companies that operate in the same segment as Feldan (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Feldan
Feldan was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Feldan is headquartered in Quebec City, Canada. It is registered at Quebec City, Quebec, Canada.
Feldan is a funded company, having raised a total of $52.9M across 9 funding rounds to date. The company's 1st funding round was a Grant of $450K, raised on Apr 2009.
The company was founded in 2007 in Quebec City, Canada, and operates in the regenerative medicine sector. Therapeutics are developed using the Feldan Shuttle platform, which enables direct delivery of proteins, such as nucleases or transcription factors, to specific cellular compartments. Challenges associated with nucleic acid delivery are addressed, facilitating regulatory processes and clinical translations. In-house applications are pursued alongside collaborations with partners.
Feldan's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Feldan offers Feldan Shuttle.
Feldan has 13 investors. Key investors include Amgen, Cystic Fibrosis Foundation, GC Green Cross Lab Cell, Zynext Ventures, and Linearis.